DOCSLIB.ORG

Identification of P450 Oxidoreductase As a Major Determinant of Sensitivity to Hypoxia-Activated Prodrugs

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Identification of P450 Oxidoreductase As a Major Determinant of Sensitivity to Hypoxia-Activated Prodrugs Published OnlineFirst August 21, 2015; DOI: 10.1158/0008-5472.CAN-15-1107 Cancer Therapeutics, Targets, and Chemical Biology Research Identification of P450 Oxidoreductase as a Major Determinant of Sensitivity to Hypoxia-Activated Prodrugs Francis W. Hunter1, Richard J. Young2,3, Zvi Shalev4, Ravi N. Vellanki4, Jingli Wang1, Yongchuan Gu1,5, Naveen Joshi1, Sreevalsan Sreebhavan1, Ilan Weinreb4, David P. Goldstein6, Jason Moffat7, Troy Ketela8, Kevin R. Brown8, Marianne Koritzinsky4,7,9, Benjamin Solomon2,3,10, Danny Rischin3,10, William R. Wilson1, and Bradly G. Wouters4,7,11,12 Abstract Hypoxia is a prevalent feature of many tumors contributing SN30000 in three different genetic backgrounds. No other to disease progression and treatment resistance, and therefore genes consistently modified SN30000 sensitivity, even within constitutes an attractive therapeutic target. Several hypoxia- a POR-negative background. Knockdown or genetic knockout activated prodrugs (HAP) have been developed, including of POR reduced SN30000 reductive metabolism and clono- the phase III candidate TH-302 (evofosfamide) and the pre- genic cell death and similarly reduced sensitivity to TH-302 clinical agent SN30000, which is an optimized analogue of the under hypoxia. A retrospective evaluation of head and neck well-studied HAP tirapazamine. Experience with this therapeu- squamous cell carcinomas showed heterogeneous POR expres- tic class highlights an urgent need to identify biomarkers of sion and suggested a possible relationship between human HAP sensitivity, including enzymes responsible for prodrug papillomavirus status and HAP sensitivity. Taken together, our activation during hypoxia. Using genome-scale shRNA screens study identifies POR as a potential predictive biomarker of and a high-representation library enriched for oxidoreductases, HAP sensitivity that should be explored during the clinical we identified the flavoprotein P450 (cytochrome) oxidoreduc- development of SN30000, TH-302, and other hypoxia-directed tase (POR) as the predominant determinant of sensitivity to agents. Cancer Res; 75(19); 1–13. Ó2015 AACR. Introduction ination (2) and resistance to ionizing radiation (3). Reflecting these effects, hypoxia has been compellingly linked to adverse Hypoxia is a prevalent feature of the tumor microenvironment outcome in malignancies for which radiotherapy is administered that has been implicated in neoplastic progression (1), dissem- with curative intent (4), and agents that target tumor hypoxia promise to improve outcomes in radiation oncology. Hypoxia-activated prodrugs (HAP) have been developed to 1 Auckland Cancer Society Research Centre, Faculty of Medical and target hypoxic tissue (5). HAPs are metabolized, typically by Health Sciences, University of Auckland, Auckland, New Zealand. 2Research Division, Peter MacCallum Cancer Centre, East Melbourne, flavoenzyme-catalyzed one-electron reduction, to a prodrug rad- Victoria, Australia. 3Sir Peter MacCallum Department of Oncology, ical from which an active cytotoxin is subsequently derived (6). In 4 University of Melbourne, Parkville, Victoria, Australia. Princess Mar- the presence of oxygen, the radical is back-oxidized to the initial garet Cancer Centre, University Health Network, Toronto, Ontario, Canada. 5AnQual Laboratories, School of Pharmacy, Faculty of Med- prodrug, and in this manner HAPs exploit hypoxia to achieve ical and Health Sciences, University of Auckland, Auckland, New selectivity (6). The most advanced clinical agent in this class is the 6 Zealand. Department of Otolaryngology–Head and Neck Surgery, nitroimidazole mustard evofosfamide (TH-302; refs. 7, 8), which University of Toronto,Toronto, Ontario, Canada. 7Department of Radi- ation Oncology, University of Toronto,Toronto,Ontario,Canada. 8Don- is in phase III trials for pancreatic adenocarcinoma and soft tissue nelly Centre and Banting and Best Department of Medical Research, sarcoma (NCT01746979 and NCT01440088). 9 University of Toronto, Toronto, Ontario, Canada. Institute of Medical The benzotriazine di-N-oxide tirapazamine (TPZ) is the most Science, University of Toronto, Toronto, Ontario, Canada. 10Depart- ment of Medical Oncology, Peter MacCallum Cancer Centre, East thoroughly studied HAP (9). Metabolic activation of TPZ releases Melbourne, Victoria, Australia. 11Department of Medical Biophysics, free radicals that damage DNA (10) and selectively kill hypoxic University of Toronto,Toronto, Ontario, Canada. 12Ontario Institute for cells (11). TPZ showed promising activity in early clinical studies Cancer Research, Toronto, Ontario, Canada. (12, 13). However, the addition of TPZ to chemoradiotherapy Note: Supplementary data for this article are available at Cancer Research for head and neck squamous cell carcinoma (HNSCC) failed to Online (http://cancerres.aacrjournals.org/). extend survival in a pivotal trial (14). This disappointing out- Corresponding Author: Bradly G. Wouters, Princess Margaret Cancer Research come has been attributed to poor compliance with radiotherapy Tower, MaRS Centre, 12th Floor Room 12-401, 101 College Street, Toronto, ON, protocols at some centers (15), differential impact of TPZ in M5G 1L7, Canada. Phone: 416-581-7861; Fax: 416-946-2984; E-mail: HPV-positive and -negative tumors (16) and failure to select pati- [email protected] ents for presence of tumor hypoxia (17, 18). Moreover, TPZ shows doi: 10.1158/0008-5472.CAN-15-1107 poor tumor penetration (19–21), a liability that is corrected in the Ó2015 American Association for Cancer Research. second-generation TPZ analogue SN30000 (Fig. 1A), which was www.aacrjournals.org OF1 Downloaded from cancerres.aacrjournals.org on October 1, 2021. © 2015 American Association for Cancer Research. Published OnlineFirst August 21, 2015; DOI: 10.1158/0008-5472.CAN-15-1107 Hunter et al. A O- B N+ N O Lentiviruses armed with NH+ barcoded shRNAs N+ O- SN30000 O - 2 Infection 1e, H+ reductases O2 - Puro SN30000 Recovery O 1-oxide O HKO1 Selection treatment N N+ HKO2 N N HT-29 PANC-1 N N SN30000 OH radical O- BDZ radical Barcode sequencing (cytotoxin) nor-oxide N+ N N N N N C HT-29 D PANC1 4 4 shRNA24 shRNA24 shRNA26 shRNA26 shRNA27 3 2 shRNA27 2 0 1 0 Z-score − Z-score 2 All genes −1 All genes POR POR −2 −4 −3 −6 −4 HKO2 E 4 F 4 shRNA24 All genes shRNA26 3 POR shRNA27 2 2 1 0 0 Z-score All genes − −2 1 POR Z-score (PANC-1) −2 −4 −3 − 4 −6 −6 −4 −2 420 Z-score (HT-29) Figure 1. High-throughput SN30000 reductase shRNA screens in carcinoma cell lines. A, chemical structure of the benzotriazine di-N-oxide HAP SN30000 and its reductive metabolism to the cytotoxic benzodiazinyl (BDZ) radical, as based on (27). B, schematic overview of the SN30000 screening workflow used in this study. C and D, waterfall plots of Z-scores for shRNA enrichment factors, arrayed by ascending magnitude of effect, for HT-29 and PANC-1. The colored fields indicate Z > 1.96. Data points corresponding to POR-targeted hairpins are highlighted in red with specific shRNAs labeled. E, scatter plot of Z-scores for all unique shRNAs in the HT-29 and PANC-1 reductase screens. Gray fields indicate Z > 1.96 for either line, with the red field indicating Z > 1.96 in both genetic backgrounds. As for B, POR hairpins are colored red with the three shRNA significantly selected in both cell lines labeled. F, waterfall plot of Z-scores for shRNA enrichment factors, arrayed by ascending magnitude of effect, for the HKO2 (PORÀ/À) reductase screen. OF2 Cancer Res; 75(19) October 1, 2015 Cancer Research Downloaded from cancerres.aacrjournals.org on October 1, 2021. © 2015 American Association for Cancer Research. Published OnlineFirst August 21, 2015; DOI: 10.1158/0008-5472.CAN-15-1107 POR Is a Major Determinant of Sensitivity to HAPs developed using a lead selection algorithm that explicitly con- months cumulative passage from frozen stocks confirmed to be sidered extravascular transport (21, 22). These agents are equiv- Mycoplasma-free by PCR-ELISA (Roche Diagnostics). Cell lines alent in mechanism of action (22–24) and nonclinical toxicology were authenticated by commercial suppliers (HCT116, PANC-1, (22); however, SN30000 provides superior plasma pharmacoki- HEK293T) or by short tandem repeat (STR) profiling (HT-29). netics in rodents, shows faster diffusion through three-dimen- sional cell cultures and is more active in multiple xenografts (22). High-throughput shRNA screens Experience with this therapeutic class suggests that selecting As a screening library, we used the Sigma MISSION TRC1 tumors that express the intended target is essential for optimizing lentiviral shRNA pool, which encompasses 82,017 barcoded their clinical use. However, biomarkers of sensitivity to HAPs are shRNAs targeting 16,019 genes (33). Generation of a custom poorly defined and this remains a major challenge in patient "reductase" library of 1,821 shRNAs covering 359 genes, includ- stratification. Prior studies have focused on known aspects of HAP ing the majority of annotated human flavoproteins, is described pharmacology, such as hypoxia (17), and the role of DNA- in Supplementary Methods. We designed pharmacologically rel- damage responses (10, 23, 25, 26). Reductive activation is also evant shRNA screens using SN30000 exposures consistent with a requirement for HAP effect; however, the identity of enzymes plasma pharmacokinetics achieved below murine MTD (22). that activate HAPs, their potential as sensitivity biomarkers, and Screens were calibrated to robustly detect (Z-scores > 1.96) hair- variation of their expression
Load more

Recommended publications
  • Exploiting the Cancer Niche: Tumor-Associated Macrophages and Hypoxia As Promising Synergistic Targets for Nano-Based Therapy
    Accepted Manuscript Exploiting the cancer niche: Tumor-associated macrophages and hypoxia as promising synergistic targets for nano-based therapy Vera Silva, Wafa' T. Al-Jamal PII: S0168-3659(17)30118-9 DOI: doi: 10.1016/j.jconrel.2017.03.013 Reference: COREL 8698 To appear in: Journal of Controlled Release Received date: 17 December 2016 Revised date: 5 March 2017 Accepted date: 7 March 2017 Please cite this article as: Vera Silva, Wafa' T. Al-Jamal , Exploiting the cancer niche: Tumor-associated macrophages and hypoxia as promising synergistic targets for nano- based therapy. The address for the corresponding author was captured as affiliation for all authors. Please check if appropriate. Corel(2017), doi: 10.1016/j.jconrel.2017.03.013 This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain. ACCEPTED MANUSCRIPT Exploiting the cancer niche: tumor-associated macrophages and hypoxia as promising synergistic targets for nano-based therapy Vera Silva1 and Wafa’ T. Al-Jamal1,* 1School of Pharmacy - University of East Anglia, Norwich Research Park, Norwich, NR4 7TJ, United Kingdom * To whom correspondence should be addressed: Dr W. T. Al-Jamal School of Pharmacy University of East Anglia Norwich Research Park Norwich NR4 7TJ (UK) E-mail: [email protected] ACCEPTED MANUSCRIPT 1 ACCEPTED MANUSCRIPT Abstract The tumor microenvironment has been widely exploited as an active participant in tumor progression.
    [Show full text]
  • Proteomic and Metabolomic Analyses of Mitochondrial Complex I-Deficient
    THE JOURNAL OF BIOLOGICAL CHEMISTRY VOL. 287, NO. 24, pp. 20652–20663, June 8, 2012 © 2012 by The American Society for Biochemistry and Molecular Biology, Inc. Published in the U.S.A. Proteomic and Metabolomic Analyses of Mitochondrial Complex I-deficient Mouse Model Generated by Spontaneous B2 Short Interspersed Nuclear Element (SINE) Insertion into NADH Dehydrogenase (Ubiquinone) Fe-S Protein 4 (Ndufs4) Gene*□S Received for publication, November 25, 2011, and in revised form, April 5, 2012 Published, JBC Papers in Press, April 25, 2012, DOI 10.1074/jbc.M111.327601 Dillon W. Leong,a1 Jasper C. Komen,b1 Chelsee A. Hewitt,a Estelle Arnaud,c Matthew McKenzie,d Belinda Phipson,e Melanie Bahlo,e,f Adrienne Laskowski,b Sarah A. Kinkel,a,g,h Gayle M. Davey,g William R. Heath,g Anne K. Voss,a,h René P. Zahedi,i James J. Pitt,j Roman Chrast,c Albert Sickmann,i,k Michael T. Ryan,l Gordon K. Smyth,e,f,h b2 a,h,m,n3 David R. Thorburn, and Hamish S. Scott Downloaded from From the aMolecular Medicine Division, gImmunology Division, and eBioinformatics Division, Walter and Eliza Hall Institute of Medical Research, Parkville, Victoria 3052, Australia, the bMurdoch Childrens Research Institute, Royal Children’s Hospital and Department of Paediatrics, University of Melbourne, Parkville, Victoria 3052, Australia, the cDépartement de Génétique Médicale, Université de Lausanne, 1005 Lausanne, Switzerland, the dCentre for Reproduction and Development, Monash Institute of Medical Research, Clayton, Victoria 3168, Australia, the hDepartment of Medical Biology
    [Show full text]
  • Tumour Hypoxia-Mediated Immunosuppression: Mechanisms and Therapeutic Approaches to Improve Cancer Immunotherapy
    cells Review Tumour Hypoxia-Mediated Immunosuppression: Mechanisms and Therapeutic Approaches to Improve Cancer Immunotherapy Zhe Fu 1,2, Alexandra M. Mowday 2,3 , Jeff B. Smaill 2,3, Ian F. Hermans 1,2 and Adam V. Patterson 2,3,* 1 Malaghan Institute of Medical Research, Wellington 6042, New Zealand; [email protected] (Z.F.); [email protected] (I.F.H.) 2 Maurice Wilkins Centre for Molecular Biodiscovery, Auckland, University of Auckland, Auckland 1142, New Zealand; [email protected] (A.M.M.); [email protected] (J.B.S.) 3 Auckland Cancer Society Research Centre, School of Medical Sciences, University of Auckland, Auckland 1142, New Zealand * Correspondence: [email protected] Abstract: The magnitude of the host immune response can be regulated by either stimulatory or inhibitory immune checkpoint molecules. Receptor-ligand binding between inhibitory molecules is often exploited by tumours to suppress anti-tumour immune responses. Immune checkpoint inhibitors that block these inhibitory interactions can relieve T-cells from negative regulation, and have yielded remarkable activity in the clinic. Despite this success, clinical data reveal that durable responses are limited to a minority of patients and malignancies, indicating the presence of underlying resistance mechanisms. Accumulating evidence suggests that tumour hypoxia, a pervasive feature of many solid cancers, is a critical phenomenon involved in suppressing the anti-tumour immune Citation: Fu, Z.; Mowday, A.M.; response generated by checkpoint inhibitors. In this review, we discuss the mechanisms associated Smaill, J.B.; Hermans, I.F.; Patterson, with hypoxia-mediate immunosuppression and focus on modulating tumour hypoxia as an approach A.V.
    [Show full text]
  • Supplementary Materials
    Supplementary Materials COMPARATIVE ANALYSIS OF THE TRANSCRIPTOME, PROTEOME AND miRNA PROFILE OF KUPFFER CELLS AND MONOCYTES Andrey Elchaninov1,3*, Anastasiya Lokhonina1,3, Maria Nikitina2, Polina Vishnyakova1,3, Andrey Makarov1, Irina Arutyunyan1, Anastasiya Poltavets1, Evgeniya Kananykhina2, Sergey Kovalchuk4, Evgeny Karpulevich5,6, Galina Bolshakova2, Gennady Sukhikh1, Timur Fatkhudinov2,3 1 Laboratory of Regenerative Medicine, National Medical Research Center for Obstetrics, Gynecology and Perinatology Named after Academician V.I. Kulakov of Ministry of Healthcare of Russian Federation, Moscow, Russia 2 Laboratory of Growth and Development, Scientific Research Institute of Human Morphology, Moscow, Russia 3 Histology Department, Medical Institute, Peoples' Friendship University of Russia, Moscow, Russia 4 Laboratory of Bioinformatic methods for Combinatorial Chemistry and Biology, Shemyakin-Ovchinnikov Institute of Bioorganic Chemistry of the Russian Academy of Sciences, Moscow, Russia 5 Information Systems Department, Ivannikov Institute for System Programming of the Russian Academy of Sciences, Moscow, Russia 6 Genome Engineering Laboratory, Moscow Institute of Physics and Technology, Dolgoprudny, Moscow Region, Russia Figure S1. Flow cytometry analysis of unsorted blood sample. Representative forward, side scattering and histogram are shown. The proportions of negative cells were determined in relation to the isotype controls. The percentages of positive cells are indicated. The blue curve corresponds to the isotype control. Figure S2. Flow cytometry analysis of unsorted liver stromal cells. Representative forward, side scattering and histogram are shown. The proportions of negative cells were determined in relation to the isotype controls. The percentages of positive cells are indicated. The blue curve corresponds to the isotype control. Figure S3. MiRNAs expression analysis in monocytes and Kupffer cells. Full-length of heatmaps are presented.
    [Show full text]
  • Supplementary Table S4. FGA Co-Expressed Gene List in LUAD
    Supplementary Table S4. FGA co-expressed gene list in LUAD tumors Symbol R Locus Description FGG 0.919 4q28 fibrinogen gamma chain FGL1 0.635 8p22 fibrinogen-like 1 SLC7A2 0.536 8p22 solute carrier family 7 (cationic amino acid transporter, y+ system), member 2 DUSP4 0.521 8p12-p11 dual specificity phosphatase 4 HAL 0.51 12q22-q24.1histidine ammonia-lyase PDE4D 0.499 5q12 phosphodiesterase 4D, cAMP-specific FURIN 0.497 15q26.1 furin (paired basic amino acid cleaving enzyme) CPS1 0.49 2q35 carbamoyl-phosphate synthase 1, mitochondrial TESC 0.478 12q24.22 tescalcin INHA 0.465 2q35 inhibin, alpha S100P 0.461 4p16 S100 calcium binding protein P VPS37A 0.447 8p22 vacuolar protein sorting 37 homolog A (S. cerevisiae) SLC16A14 0.447 2q36.3 solute carrier family 16, member 14 PPARGC1A 0.443 4p15.1 peroxisome proliferator-activated receptor gamma, coactivator 1 alpha SIK1 0.435 21q22.3 salt-inducible kinase 1 IRS2 0.434 13q34 insulin receptor substrate 2 RND1 0.433 12q12 Rho family GTPase 1 HGD 0.433 3q13.33 homogentisate 1,2-dioxygenase PTP4A1 0.432 6q12 protein tyrosine phosphatase type IVA, member 1 C8orf4 0.428 8p11.2 chromosome 8 open reading frame 4 DDC 0.427 7p12.2 dopa decarboxylase (aromatic L-amino acid decarboxylase) TACC2 0.427 10q26 transforming, acidic coiled-coil containing protein 2 MUC13 0.422 3q21.2 mucin 13, cell surface associated C5 0.412 9q33-q34 complement component 5 NR4A2 0.412 2q22-q23 nuclear receptor subfamily 4, group A, member 2 EYS 0.411 6q12 eyes shut homolog (Drosophila) GPX2 0.406 14q24.1 glutathione peroxidase
    [Show full text]
  • Sarcoma Field Digests Evofosfamide Failure
    December 08, 2015 Sarcoma field digests evofosfamide failure Robin Davison The failure of the phase III study of evofosfamide in soft tissue sarcoma – which was itself only half of an unprecedented double dose of disappointment meted out to Threshold Pharmaceuticals yesterday – has left observers pondering the implications for future development in this cancer field. Most obviously, Threshold’s discontinuation of evofosfamide leaves an already thin pipeline in this indication even thinner (see table below). And the sarcoma field has never had a very strong flow of new agents. That industry pipeline for soft tissue sarcoma is now reduced to just five molecules in late-stage or pivotal studies – two in phase III and three in phase II/III – with a similar number in company-sponsored, randomised phase II studies. There are of course a number of other agents in investigator-sponsored or exploratory, single- arm studies in sarcoma, but these have been excluded from EP Vantage’s analysis as they do not, or do not yet, represent programmes working towards a regulatory approval. Curiously, the fact that evofosfamide did not show an additive benefit to doxorubicin in the pivotal study had to some extent been anticipated by investors (Event – Threshold hopes to buck the F-R rule, December 3, 2015). This was based on concerns that the study had underestimated control arm survival and thus would be underpowered to show an effect. While this may or may not have been evofosfamide’s undoing, what was unexpected was an exceptional performance in the doxorubicin-only control arm. The study showed a median overall survival of 19 months for the control arm, by far the longest seen yet for the existing agent.
    [Show full text]
  • Evofosfamide for Locally Advanced, Unresectable Or Metastatic Pancreatic Cancer – First Line in Combination with Gemcitabine
    Horizon Scanning Centre March 2015 Evofosfamide for locally advanced, unresectable or metastatic pancreatic cancer – first line in combination with gemcitabine SUMMARY NIHR HSC ID: 7060 Evofosfamide is intended to be used as a first line treatment option for patients with locally advanced, unresectable or metastatic (late stage) This briefing is pancreatic cancer. Evofosfamide is an intravenously administered, cytotoxic, hypoxia-activated prodrug (HAP), it is a nitromidazole-linked prodrug of based on dibromo isophoramide mustard, a potent DNA alkylator. Evofosfamide is information essentially inactive under normal oxygen levels. The trigger molecule keeps available at the time the toxin inactive until it is in the hypoxic region of the tumour so as to of research and a prevent general toxicity and it is activated by the low oxygen concentrations limited literature thus killing cells in its vicinity. Evofosfamide is administered at 340mg/m2 in search. It is not combination with 1,000mg/m2 gemcitabine, both via intravenous (IV) infusion intended to be a over 30 minutes on days 1, 8 and 15 of every 28 day cycle. definitive statement on the safety, Pancreatic cancer affects both sexes equally, with a lifetime risk of I in 77 for efficacy or men and 1 in 79 for women. In the UK, around 8,800 people were effectiveness of the diagnosed with pancreatic cancer in 2011. Pancreatic cancer has one of the health technology worst prognoses of all solid tumours with >95% of those affected dying of covered and should their disease. not be used for commercial As the majority of pancreatic cancer is diagnosed at an advanced stage, the purposes or aim of treatment is usually palliative; to improve quality of life and relieve commissioning symptoms.
    [Show full text]
  • Supercomplexes of Prokaryotic Aerobic Respiratory Chains Escherichia Coli and Bacillus Subtilis Supramolecular Assemblies Pedro M.F
    Supercomplexes of Prokaryotic Aerobic Respiratory Chains Escherichia coli and Bacillus subtilis supramolecular assemblies Pedro M.F. Sousa Dissertation presented to obtain the Ph.D degree in Biochemistry Instituto de Tecnologia Química e Biológica | Universidade Nova de Lisboa Instituto de Investigação Científica Tropical Oeiras, December, 2013 Supercomplexes of Prokaryotic Aerobic Respiratory Chains Escherichia coli and Bacillus subtilis supramolecular assemblies Pedro M.F. Sousa Dissertation presented to obtain the Ph.D degree in Biochemistry Instituto de Tecnologia Química e Biológica | Universidade Nova de Lisboa Instituto de Investigação Científica Tropical Supervisor: Ana M.P. Melo Co-supervisor: Miguel Teixeira Oeiras, December, 2013 From left to right: Prof. Miguel Teixeira, Dr. Lígia Saraiva, Prof. Carlos Romão, Prof. Thorsten Friedrich, Pedro Sousa, Dr. Margarida Duarte, Prof. João Arrabaça, Dr. Ana Melo. Instituto de Investigação Científica Tropical (IICT) Rua da Junqueira Nº86, 1º 1300-344 Lisboa Portugal Tel. (+351) 213 616 340 Instituto de Tecnologia Química e Biológica (ITQB) Av. da República Estação Agronómica Nacional 2780-157 Oeiras Portugal Tel. (+351) 214 469 323 The molecular cup is now empty. The time has come to replace the purely reductionist “eyes-down” molecular perspective with a new and genuinely holistic “eyes-up” view of the living world, one whose primary focus is on evolution, emergence, and biology’s innate complexity. Carl R.Woese (1928 – 2012) in “A new biology for a new century” Microbiology and Molecular Biology Reviews 68(2), 173 – 186 (2004) Acknowledgements The work summarized in this thesis is the product of several collaborations established during my research grant. It is with great appreciation that I would like to acknowledge the following groups and people: Ana Melo, my supervisor, for her endless support on my work.
    [Show full text]
  • Munkácsy E. & Rea, S. L. the Paradox Of
    NIH Public Access Author Manuscript Exp Gerontol. Author manuscript; available in PMC 2015 August 01. NIH-PA Author ManuscriptPublished NIH-PA Author Manuscript in final edited NIH-PA Author Manuscript form as: Exp Gerontol. 2014 August ; 56: 221–233. doi:10.1016/j.exger.2014.03.016. The Paradox of Mitochondrial Dysfunction and Extended Longevity Erin Munkácsy1,2 and Shane L. Rea1,3,* 1Barshop Institute for Longevity and Aging Studies, University of Texas Health Science Center at San Antonio, San Antonio, TX, 78245-3207 USA 2Department of Cell and Structural Biology, University of Texas Health Science Center at San Antonio, San Antonio, TX, 78245-3207 USA 3Department of Physiology, University of Texas Health Science Center at San Antonio, San Antonio, TX, 78245-3207 USA Abstract Mitochondria play numerous, essential roles in the life of eukaryotes. Disruption of mitochondrial function in humans is often pathological or even lethal. Surprisingly, in some organisms mitochondrial dysfunction can result in life extension. This paradox has been studied most extensively in the long-lived Mit mutants of the nematode Caenorhabditis elegans. In this review, we explore the major responses that are activated following mitochondrial dysfunction in these animals and how these responses potentially act to extend their life. We focus our attention on five broad areas of current research – reactive oxygen species signaling, the mitochondrial unfolded protein response, autophagy, metabolic adaptation, and the roles played by various transcription factors. Lastly, we also examine why disruption of complexes I and II differ in their ability to induce the Mit phenotype and extend lifespan. Keywords C. elegans; Mitochondria; Mit Mutant; Lifespan; Aging; Metabolism 1.
    [Show full text]
  • Management of Metastatic Pancreatic Adenocarcinoma
    Management of Metastatic Pancreatic Adenocarcinoma a,b c,d, Ahmad R. Cheema, MD , Eileen M. O’Reilly, MD * KEYWORDS Pancreatic cancer Metastatic disease Gemcitabine Nab-paclitaxel FOLFIRINOX Targeted agents Immune therapy KEY POINTS Progress in the treatment of pancreatic ductal adenocarcinoma (PDAC) has been incre- mental, mainly ensuing from cytotoxic systemic therapy, which continues to be a standard of care for metastatic disease. Folinic acid, 5-fluorouracil (5-FU), irinotecan, and oxaliplatin (FOLFIRINOX) and gemcita- bine plus nab-paclitaxel have emerged as new standard therapies, improving survival in patients with good performance status. Novel therapeutics targeting the peritumoral stroma and tumor-driven immune suppres- sion are currently a major focus of research in metastatic disease. Identification of reliable and validated predictive biomarkers to optimize therapeutics con- tinues to be a challenge. Continued efforts toward better understanding of tumor biology and developing new drugs are warranted because a majority of patients succumb within a year of diagnosis, despite an increasing number of therapeutic options available today. INTRODUCTION In the year 2016, there will be approximately 53,000 estimated new individuals diag- nosed with PDAC in the United States, representing approximately 3% of all cancer Financial Disclosures: None (A.R. Cheema). Research support: Sanofi Pharmaceuticals, Celgene, Astra-Zenica, MedImmune, Bristol-Myers Squibb, Incyte, Polaris, Myriad Genetics, Momenta Pharmaceuticals, OncoMed. Consulting: Celgene, MedImmune, Sanofi Pharmaceutical, Threshold Pharmaceuticals, Gilead, Merrimack (E.M. O’Reilly). Funding support: Cancer Center Support Grant (P30 CA008748). a Department of Medicine, Icahn School of Medicine at Mount Sinai, 1 Gustave Levy Pl, New York, NY 10029, USA; b Department of Medicine, Mount Sinai St.
    [Show full text]
  • Preclinical Benefit of Hypoxia-Activated Intra- Arterial
    Published OnlineFirst July 20, 2016; DOI: 10.1158/1078-0432.CCR-16-0725 Cancer Therapy: Preclinical Clinical Cancer Research Preclinical Benefit of Hypoxia-Activated Intra- arterial Therapy with Evofosfamide in Liver Cancer Rafael Duran1,2, Sahar Mirpour1, Vasily Pekurovsky1, Shanmugasundaram Ganapathy- Kanniappan1, Cory F. Brayton3, Toby C. Cornish4, Boris Gorodetski1, Juvenal Reyes5, Julius Chapiro1,2,Rudiger€ E. Schernthaner1,2, Constantine Frangakis6, MingDe Lin2,7, Jessica D. Sun8, Charles P. Hart8, and Jean-Francois¸ Geschwind2 Abstract Purpose: To evaluate safety and characterize anticancer efficacy Results: cTACE þ Evo showed a similar profile of liver of hepatic hypoxia-activated intra-arterial therapy (HAIAT) with enzymes elevation and pathologic scores compared with cTACE. evofosfamide in a rabbit model. Neither hematologic nor renal toxicity were observed. Animals Experimental Design: VX2-tumor-bearing rabbits were treated with cTACE þ Evo demonstrated smaller tumor volumes, assigned to 4 intra-arterial therapy (IAT) groups (n ¼ 7/group): lower tumor growth rates, and higher necrotic fractions com- (i) saline (control); (ii) evofosfamide (Evo); (iii) doxorubicin– pared with cTACE. cTACE þ Evo resulted in a marked reduction lipiodol emulsion followed by embolization with 100–300 mm in the HF and HC. Correlation was observed between decreases beads (conventional, cTACE); or (iv) cTACE and evofosfamide in HF or HC and tumor necrosis. cTACE þ Evo promoted (cTACE þ Evo). Blood samples were collected pre-IAT and 1, 2, 7, antitumor effects as evidenced by increased expression of and 14 days post-IAT. A semiquantitative scoring system assessed g-H2AX, apoptotic biomarkers, and decreased cell proliferation. hepatocellular damage. Tumor volumes were segmented on Increased HIF1a/VEGF expression and tumor glycolysis sup- multidetector CT (baseline, 7/14 days post-IAT).
    [Show full text]
  • Integrated Proteomic and Mirna Transcriptional Analysis Reveals the Hepatotoxicity Mechanism of PFNA Exposure in Mice
    Integrated proteomic and miRNA transcriptional analysis reveals the hepatotoxicity mechanism of PFNA exposure in mice Jianshe Wang, Shengmin Yan, Wei Zhang, Jiayin Dai * Key Laboratory of Animal Ecology and Conservation Biology, Institute of Zoology, Chinese Academy of Sciences, Beijing, 100101, P.R. China *Corresponding author: Dai JY; Tel. +86-10-64807185; E-mail: [email protected] Supplementary materials and methods PFNA concentration detection in the serum and liver PFNA in liver and serum samples were quantified using HPLC-MS/MS. Briefly, samples with internal standard were extracted with 5 mL of acetonitrile in 15 mL polypropylene (PP) tubes, and all tubes were placed on a mechanical shaker for 20 min followed by centrifugation at 3,000 × g for 10 min. The top layers, which contained PFNA (analytes and internal standard), were transferred into new PP tubes. The extraction procedure was repeated and a final solution of 10 mL of acetonitrile was combined and concentrated to 0.5 mL under nitrogen gas at 40°C. After the addition of 0.5 mL methanol, the final solution was diluted into 10 mL Milli-Q water for SPE cleanup. All samples were then extracted using an Oasis WAX cartridge (Oasis1 HLB; 150 mg, 6 cc; Waters). The cartridge was pre-equilibrated by the addition of a sequence of 4 mL of 0.1% NH 4OH in methanol, 4 mL methanol, and 4 mL water at a rate of 1 drop per second. Samples (11 mL) were then passed through these cartridges at a rate of 1 drop per second. After loading all samples, cartridges were rinsed with 5 mL Milli-Q water and then washed with 4 mL of 25 mM acetate buffer solution (pH 4).
    [Show full text]